Group One Trading’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-21,403
| Closed | -$3.46M | – | 8210 |
|
|
2025
Q3 | $2.05M | Buy |
+21,403
| New | +$1.37M | ﹤0.01% | 2299 |
|
|
2023
Q3 | – | Sell |
-332
| Closed | -$6.52K | – | 7685 |
|
|
2023
Q2 | $7.51K | Sell |
332
-1,229
| -79% | -$28.9K | ﹤0.01% | 6540 |
|
|
2023
Q1 | $39.7K | Buy |
+1,561
| New | +$44.3K | ﹤0.01% | 5027 |
|
|
2022
Q4 | – | Sell |
-20
| Closed | – | – | 7299 |
|
|
2022
Q3 | $0 | Hold |
20
| – | – | ﹤0.01% | 7586 |
|
|
2022
Q2 | $0 | Buy |
+20
| New | +$247 | ﹤0.01% | 7865 |
|
|
2021
Q4 | – | Sell |
-577
| Closed | -$18K | – | 8247 |
|
|
2021
Q3 | $26K | Buy |
+577
| New | +$21.9K | ﹤0.01% | 7008 |
|
|
2020
Q2 | – | Sell |
-2
| Closed | -$130 | – | 5807 |
|
|
2020
Q1 | $0 | Sell |
2
-13
| -87% | -$779 | ﹤0.01% | 5295 |
|
|
2019
Q4 | $1K | Hold |
15
| – | – | ﹤0.01% | 4965 |
|
|
2019
Q3 | $1K | Sell |
15
-5
| -25% | -$168 | ﹤0.01% | 4972 |
|
|
2019
Q2 | $1K | Hold |
20
| – | – | ﹤0.01% | 4807 |
|
|
2019
Q1 | $1K | Hold |
20
| – | – | ﹤0.01% | 4650 |
|
|
2018
Q4 | $1K | Hold |
20
| – | – | ﹤0.01% | 4713 |
|
|
2018
Q3 | $2K | Sell |
20
-3
| -13% | -$265 | ﹤0.01% | 5007 |
|
|
2018
Q2 | $2K | Sell |
23
-28
| -55% | -$2.64K | ﹤0.01% | 4933 |
|
|
2018
Q1 | $4K | Buy |
+51
| New | +$6.97K | ﹤0.01% | 4541 |
|
Group One Trading's CDTX Position: Q4 2025 in Review
Group One Trading sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 21,403 shares — an estimated $3.46M sold.
Group One Trading first reported a position in CDTX in Q1 2018 and held it in 15 quarters. The position peaked at $2.05M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.
- Group One Trading reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 21,403 Cidara Therapeutics shares in Q4 2025, an estimated $3.46M.
- Group One Trading first reported a position in Cidara Therapeutics in Q1 2018 and held it in 15 quarters.
- Group One Trading's Cidara Therapeutics position peaked at $2.05M in Q3 2025.
- 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.